{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:12:06Z","timestamp":1761898326224,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.clinre.2015.02.005","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T07:58:33Z","timestamp":1428307113000},"page":"555-565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases"],"prefix":"10.1016","volume":"39","author":[{"given":"Prashant","family":"Pandya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi","family":"Rzouq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olurinde","family":"Oni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clinre.2015.02.005_bib0265","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/jlts.2003.50073","article-title":"Projecting future complications of chronic hepatitis C in the United States","volume":"9","author":"Davis","year":"2003","journal-title":"Liver Transpl"},{"issue":"10","key":"10.1016\/j.clinre.2015.02.005_bib0270","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Int Med"},{"issue":"7","key":"10.1016\/j.clinre.2015.02.005_bib0275","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00535-007-2064-6","article-title":"The epidemiology of hepatitis C infection in the United States","volume":"42","author":"Rustgi","year":"2007","journal-title":"J Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2015.02.005_bib0280","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American association for the study of liver diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.clinre.2015.02.005_bib0285","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clinre.2015.02.005_bib0290","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clinre.2015.02.005_bib0295","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.2014.7085","article-title":"Treatment of hepatitis C: a systematic review","volume":"312","author":"Kohli","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.clinre.2015.02.005_bib0300","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/apt.12871","article-title":"Cost-effectiveness analysis of sofosbuvir plus peginterferon\/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection","volume":"40","author":"Saab","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.clinre.2015.02.005_bib0305","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/CMR.13.2.223","article-title":"Clinical significance of hepatitis C virus genotypes","volume":"13","author":"Zein","year":"2000","journal-title":"Clin Microbiol Rev"},{"issue":"7265","key":"10.1016\/j.clinre.2015.02.005_bib0310","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.clinre.2015.02.005_bib0315","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1053\/j.gastro.2010.07.005","article-title":"A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice","volume":"139","author":"Tillmann","year":"2010","journal-title":"Gastroenterology"},{"issue":"7262","key":"10.1016\/j.clinre.2015.02.005_bib0320","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.clinre.2015.02.005_bib0325","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1053\/j.gastro.2010.02.009","article-title":"Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin","volume":"138","author":"McCarthy","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.clinre.2015.02.005_bib0330","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hep.22916","article-title":"Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development","volume":"50","author":"Delang","year":"2009","journal-title":"Hepatology"},{"issue":"26","key":"10.1016\/j.clinre.2015.02.005_bib0335","doi-asserted-by":"crossref","first-page":"15865","DOI":"10.1073\/pnas.2237238100","article-title":"Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation","volume":"100","author":"Ye","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.clinre.2015.02.005_bib0340","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1572-0241.2008.01876.x","article-title":"Fluvastatin inhibits hepatitis C replication in humans","volume":"103","author":"Bader","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinre.2015.02.005_bib0345","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/jac\/dkq002","article-title":"Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV\/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study","volume":"65","author":"Milazzo","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.clinre.2015.02.005_bib0350","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000213504","article-title":"An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads","volume":"52","author":"Sezaki","year":"2009","journal-title":"Intervirology"},{"issue":"1","key":"10.1016\/j.clinre.2015.02.005_bib0355","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.gastro.2010.08.055","article-title":"Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C","volume":"140","author":"Rao","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.clinre.2015.02.005_bib0360","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hep.23787","article-title":"Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy","volume":"52","author":"Harrison","year":"2010","journal-title":"Hepatology"},{"issue":"22","key":"10.1016\/j.clinre.2015.02.005_bib0365","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1073\/pnas.96.22.12766","article-title":"Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor","volume":"96","author":"Agnello","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.clinre.2015.02.005_bib0370","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.25501","article-title":"Role of low-density lipoprotein receptor in the hepatitis C virus life cycle","volume":"55","author":"Albecka","year":"2012","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.clinre.2015.02.005_bib0375","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1073\/pnas.0409834102","article-title":"Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids","volume":"102","author":"Kapadia","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.clinre.2015.02.005_bib0380","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jhep.2006.09.024","article-title":"The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus","volume":"46","author":"Molina","year":"2007","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2015.02.005_bib0385","doi-asserted-by":"crossref","first-page":"E416","DOI":"10.1152\/ajpendo.00091.2007","article-title":"Cell surface expression of LDL receptor in chronic hepatitis C: correlation with viral load","volume":"293","author":"Petit","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.clinre.2015.02.005_bib0390","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1042\/BC20090125","article-title":"Role of lipid metabolism in hepatitis C virus assembly and entry","volume":"102","author":"Popescu","year":"2010","journal-title":"Biol Cell"},{"issue":"1","key":"10.1016\/j.clinre.2015.02.005_bib0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2893.1996.tb00075.x","article-title":"Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins","volume":"3","author":"Prince","year":"1996","journal-title":"J Viral Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2015.02.005_bib0400","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.molcel.2005.04.004","article-title":"Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication","volume":"18","author":"Wang","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.clinre.2015.02.005_bib0405","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","article-title":"Protein prenylation: molecular mechanisms and functional consequences","volume":"65","author":"Zhang","year":"1996","journal-title":"Annu Rev Biochem"},{"issue":"40","key":"10.1016\/j.clinre.2015.02.005_bib0410","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.3748\/wjg.15.5020","article-title":"Do statins reduce hepatitis C RNA titers during routine clinical use?","volume":"15","author":"Forde","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.clinre.2015.02.005_bib0415","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.clinre.2015.02.005_bib0420","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.clinre.2015.02.005_bib0425","doi-asserted-by":"crossref","first-page":"e80304","DOI":"10.1371\/journal.pone.0080304","article-title":"Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism","volume":"8","author":"Ali","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clinre.2015.02.005_bib0430","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1440-1746.2012.07267.x","article-title":"Combination of fluvastatin with pegylated interferon\/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b","volume":"28","author":"Atsukawa","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.clinre.2015.02.005_bib0435","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2893.2011.01584.x","article-title":"An open-label randomized controlled study of pegylated interferon\/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin","volume":"19","author":"Kondo","year":"2012","journal-title":"J Viral Hepatol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.clinre.2015.02.005_bib0440","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/S0168-8278(10)60264-4","article-title":"Fluvastatin as out-of-label enhancer for early and sustained virological response in chronic hepatitis C treated with peginterferon and ribavirin","volume":"52","author":"Georgescu","year":"2010","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2015.02.005_bib0445","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2014.08.013","article-title":"Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C","volume":"62","author":"Simon","year":"2015","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2015.02.005_bib0450","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"144","author":"Singh","year":"2013","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.clinre.2015.02.005_bib0455","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.2012.44.6831","article-title":"Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection","volume":"31","author":"Tsan","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2015.02.005_bib0460","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.clinre.2015.02.005_bib0465","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","article-title":"Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial","volume":"46","author":"Lewis","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clinre.2015.02.005_bib0470","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1592\/phco.27.6.845","article-title":"Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus","volume":"27","author":"Segarra-Newnham","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.clinre.2015.02.005_bib0475","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.cgh.2006.03.014","article-title":"Incidence of statin hepatotoxicity in patients with hepatitis C","volume":"4","author":"Khorashadi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2015.02.005_bib0480","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000354541","article-title":"Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naive chronic hepatitis C Patients infected with genotypes 1 and 3","volume":"57","author":"Selic Kurincic","year":"2014","journal-title":"Intervirology"},{"issue":"1","key":"10.1016\/j.clinre.2015.02.005_bib0485","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10620-009-0959-1","article-title":"Statin therapy and serum transaminases among a cohort of HCV-infected veterans","volume":"55","author":"Henderson","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.clinre.2015.02.005_bib0490","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s10620-009-1125-5","article-title":"Statins improve ALT values in chronic hepatitis C patients with abnormal values","volume":"55","author":"Madhoun","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.1016\/j.clinre.2015.02.005_bib0495","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/QAD.0b013e3282ff8ad3","article-title":"Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV\/hepatitis C virus coinfected patients","volume":"22","author":"del Valle","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.clinre.2015.02.005_bib0500","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/1743-422X-10-299","article-title":"Role of viral and host factors in interferon based therapy of hepatitis C virus infection","volume":"10","author":"Imran","year":"2013","journal-title":"Virol J"},{"issue":"4","key":"10.1016\/j.clinre.2015.02.005_bib0505","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C","volume":"49","author":"Kau","year":"2008","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.clinre.2015.02.005_bib0510","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1365-2036.2003.01463.x","article-title":"Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C","volume":"17","author":"Lee","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.clinre.2015.02.005_bib0515","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cld.2006.08.012","article-title":"Hepatitis C virus and liver transplantation","volume":"10","author":"Verna","year":"2006","journal-title":"Clin Liver Dis"},{"issue":"4","key":"10.1016\/j.clinre.2015.02.005_bib0520","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jhep.2005.01.011","article-title":"What determines the natural history of recurrent hepatitis C after liver transplantation?","volume":"42","author":"Berenguer","year":"2005","journal-title":"J Hepatol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740115000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740115000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:22:11Z","timestamp":1761895331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740115000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S2210740115000431"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2015.02.005","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2015.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}